Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development.

case report form clinical trial heart failure randomized controlled trial

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
11 2019
Historique:
received: 03 06 2019
revised: 01 07 2019
accepted: 08 07 2019
pubmed: 12 8 2019
medline: 20 11 2020
entrez: 12 8 2019
Statut: ppublish

Résumé

The development of treatments for heart failure (HF) is challenged by burdensome clinical trials. Reducing the need for extensive data collection and increasing opportunities for data compatibility between trials may improve efficiency and reduce resource burden. The Heart Failure Collaboratory (HFC) multi-stakeholder consortium sought to create a lean case report form (CRF) for use in HF clinical trials evaluating cardiac devices. The HFC convened patients, clinicians, clinical researchers, the U.S. Food and Drug Administration (FDA), payers, industry partners, and statisticians to create a consensus core CRF. Eight recent clinical trial CRFs for the treatment of HF from 6 industry partners were analyzed. All CRF elements were systematically reviewed. Those elements deemed critical for data collection in HF clinical trials were used to construct the final, harmonized CRF. The original CRFs included 176 distinct data items covering demographics, vital signs, physical examination, medical history, laboratory and imaging testing, device therapy, medications, functional and quality of life assessment, and outcome events. The resulting, minimally inclusive CRF device contains 75 baseline data items and 6 events, with separate modular additions that can be used depending on the additional detail required for a particular intervention. The consensus electronic form is now freely available for use in clinical trials. Creation of a core CRF is important to improve clinical trial efficiency in HF device development in the United States. This living document intends to reduce clinical trial administrative burden, increase evidence integrity, and improve comparability of clinical data between trials.

Identifiants

pubmed: 31401097
pii: S2213-1779(19)30542-6
doi: 10.1016/j.jchf.2019.07.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

913-921

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL125725
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL110124
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Mitchell A Psotka (MA)

Inova Heart and Vascular Institute, Falls Church, Virginia. Electronic address: Mitchell.Psotka@inova.org.

Mona Fiuzat (M)

Department of Medicine, Duke University School of Medicine, Durham, North Carolina.

Peter E Carson (PE)

Department of Cardiology, Washington Veterans Affairs Medical Center, Washington, DC.

David P Kao (DP)

Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.

Jeffrey Cerkvenik (J)

Medtronic Inc., Minneapolis, Minnesota.

Daniel E Schaber (DE)

Medtronic Inc., Minneapolis, Minnesota.

Patrick Verta (P)

Edwards Lifesciences, Irvine, California.

Robert T Kazmierski (RT)

U.S. Food and Drug Administration, Silver Spring, Maryland.

Meir Shinnar (M)

U.S. Food and Drug Administration, Silver Spring, Maryland.

Norman Stockbridge (N)

U.S. Food and Drug Administration, Silver Spring, Maryland.

Ellis F Unger (EF)

U.S. Food and Drug Administration, Silver Spring, Maryland.

Bram Zuckerman (B)

U.S. Food and Drug Administration, Silver Spring, Maryland.

Javed Butler (J)

Department of Medicine, University of Mississippi, Jackson, Mississippi.

G Michael Felker (GM)

Division of Cardiology, Duke University Medical Center, Durham, North Carolina.

Marvin A Konstam (MA)

CardioVascular Center of Tufts Medical Center, Boston, Massachusetts.

JoAnn Lindenfeld (J)

Heart Failure and Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee.

Scott D Solomon (SD)

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.

John R Teerlink (JR)

Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, California.

Christopher M O'Connor (CM)

Inova Heart and Vascular Institute, Falls Church, Virginia.

William T Abraham (WT)

Departments of Medicine, Physiology, and Cell Biology, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH